University of Wisconsin Foundation Has $12.82 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

University of Wisconsin Foundation cut its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,541 shares of the biopharmaceutical company's stock after selling 4,189 shares during the period. Madrigal Pharmaceuticals makes up 9.3% of University of Wisconsin Foundation's portfolio, making the stock its 5th largest holding. University of Wisconsin Foundation owned about 0.19% of Madrigal Pharmaceuticals worth $12,818,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in shares of Madrigal Pharmaceuticals by 1.5% in the third quarter. Geode Capital Management LLC now owns 405,655 shares of the biopharmaceutical company's stock valued at $86,104,000 after acquiring an additional 5,801 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in Madrigal Pharmaceuticals in the fourth quarter worth approximately $1,297,000. Franklin Resources Inc. boosted its position in Madrigal Pharmaceuticals by 340.1% during the 4th quarter. Franklin Resources Inc. now owns 6,087 shares of the biopharmaceutical company's stock valued at $1,878,000 after acquiring an additional 4,704 shares in the last quarter. Barclays PLC increased its holdings in shares of Madrigal Pharmaceuticals by 159.9% in the 3rd quarter. Barclays PLC now owns 40,279 shares of the biopharmaceutical company's stock valued at $8,549,000 after acquiring an additional 24,783 shares during the period. Finally, Prudential Financial Inc. lifted its stake in shares of Madrigal Pharmaceuticals by 166.2% during the 4th quarter. Prudential Financial Inc. now owns 3,655 shares of the biopharmaceutical company's stock worth $1,128,000 after purchasing an additional 2,282 shares during the last quarter. Institutional investors own 98.50% of the company's stock.

Insiders Place Their Bets

In other news, VP Robert E. Waltermire sold 14,113 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total transaction of $4,817,049.16. Following the completion of the sale, the vice president now owns 3,728 shares of the company's stock, valued at approximately $1,272,440.96. This trade represents a 79.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William John Sibold sold 1,584 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $531,020.16. Following the transaction, the chief executive officer now owns 54,303 shares in the company, valued at $18,204,537.72. This trade represents a 2.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,492 shares of company stock valued at $11,509,707. Company insiders own 22.80% of the company's stock.

Madrigal Pharmaceuticals Stock Down 2.0 %

Madrigal Pharmaceuticals stock traded down $6.12 during mid-day trading on Friday, hitting $301.66. The company had a trading volume of 238,598 shares, compared to its average volume of 392,791. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of -12.03 and a beta of -0.69. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals, Inc. has a 1 year low of $189.00 and a 1 year high of $377.46. The business has a fifty day moving average of $329.57 and a 200 day moving average of $305.88.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, beating analysts' consensus estimates of ($4.32) by $1.61. The business had revenue of $103.32 million during the quarter, compared to analyst estimates of $97.81 million. On average, sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright upped their price target on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. B. Riley upgraded Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and boosted their price target for the stock from $236.00 to $422.00 in a research note on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Finally, Citigroup upped their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Madrigal Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $378.44.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.